^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Castration-Resistant Prostate Cancer

    Associations

    News

    Trials
    1d
    Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (clinicaltrials.gov)
    P1/2, N=90, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    Bavencio (avelumab) • peposertib (M3814) • Xofigo (radium Ra-223 dichloride)
    2d
    Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov)
    P1/2, N=1200, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • docetaxel • Lenvima (lenvatinib) • enzalutamide • abiraterone acetate • etoposide IV • prednisone • dexamethasone • Welireg (belzutifan) • vibostolimab/pembrolizumab (MK-7684A)
    2d
    Rational design and structural insights of osthole-derived selective AKR1C3 inhibitors with cellular activity. (PubMed, Bioorg Chem)
    In contrast to other coumarin-based inhibitors, osthole-derived compounds with extended C8-substitutions, interact with the SP1 pocket in a novel and distinct manner. These findings validate our design strategy of enhancing SP1 pocket binding to improve AKR1C3 selectivity over other AKR1C isoforms, and provide valuable structural insights for the further development of selective AKR1C3 inhibitors as potential therapeutics for CRPC.
    Journal
    |
    AKR1C1 (Aldo-Keto Reductase Family 1 Member C1) • AKR1C2 (Aldo-Keto Reductase Family 1 Member C2)
    3d
    ENZA-p: Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=162, Active, not recruiting, Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Trial completion date: Jan 2025 --> Dec 2026
    Trial completion date
    |
    enzalutamide • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    3d
    Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer (EPIDROP) (clinicaltrials.gov)
    P=N/A, N=100, Terminated, University Hospital, Montpellier | Trial completion date: Oct 2025 --> Jun 2026 | Recruiting --> Terminated; Flaw in the analytical technique
    Trial completion date • Trial termination
    |
    CELLSEARCH®
    3d
    Jaboticaba peel extract limits castration-resistant prostate cancer aggressiveness by counteracting EMT through steroid hormone and TGF-β signaling modulation. (PubMed, J Mol Histol)
    Sixteen-week-old mice underwent surgical and chemical castration (10 mg/Kg enzalutamide), alone or in combination with JPE (5.8 g/Kg)...Mechanistically, JPE-induced effects in castrated mice involved decrease of AR protein expression as well as ERβ beneficial actions, which included a putative stimulation of TGF-β tumor-suppressive actions. In conclusion, JPE prevented the progression of poorly differentiated tumors with CRPC traits in the TRAMP model by hampering EMT and modulating steroid hormone and TGF-β signaling.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • CDH2 (Cadherin 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
    |
    enzalutamide
    3d
    NUSAP1 mediates enzalutamide resistance in prostate cancer via Wnt/β-catenin signalling-dependent regulation of AR and AR-V7. (PubMed, Cell Signal)
    The results indicate that NUSAP1 enhanced prostate cancer ENZ resistance through activation of the Wnt/β-Catenin-AR/AR-V7 signalling pathway. Targeting NUSAP1 could offer a potential therapeutic approach to address ENZ resistance in CRPC.
    Journal
    |
    AR (Androgen receptor) • NUSAP1 (Nucleolar and Spindle Associated Protein 1)
    |
    AR splice variant 7
    |
    enzalutamide
    3d
    AI-MM_CPRC: AI Multimodal Model for Predicting CRPC Progression Risk (clinicaltrials.gov)
    P=N/A, N=500, Active, not recruiting, Guangxi Medical University
    New trial
    3d
    Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC） (clinicaltrials.gov)
    P1, N=10, Recruiting, VitsGen Therapeutics Inc.
    New P1 trial
    4d
    Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Novartis Pharmaceuticals | N=217 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCNE1 (Cyclin E1)
    |
    HER-2 negative
    |
    fulvestrant • letrozole
    6d
    PROpelSub: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) (clinicaltrials.gov)
    P3, N=110, Active, not recruiting, AstraZeneca | Trial completion date: Apr 2026 --> Feb 2027
    Trial completion date
    |
    HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib) • abiraterone acetate
    6d
    EVADE-1: A Phase 2a pilot study of evexomostat in patients with metastatic castration-resistant prostate cancer. (ACTRN12626000736347)
    P1/2, N=10, Not yet recruiting, Queensland University of Technology
    New P1/2 trial
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    evexomostat (SDX-7320)